A pivotal study on cagrilintide-semaglutide for adults with overweight or obesity and Type 2 Diabetes was published in the New England Journal of Medicine on 2025-01-01. The research, known as REDEFINE 2, investigated the combination therapy's ability to help participants with excess body weight achieve weight loss.
Background
Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, available under brand names such as Wegovy, Ozempic, and Rybelsus (oral semaglutide). This publication focuses on a combination therapy involving semaglutide and cagrilintide, an amylin analog. The study specifically addressed adults living with overweight or obesity who also have Type 2 Diabetes.
Trial design
The published research, referred to as REDEFINE 2, was designed to evaluate the effectiveness of cagrilintide-semaglutide in adults diagnosed with Type 2 Diabetes and who also have excess body weight. The primary objective of the study was to assess how well this combination therapy could facilitate weight loss in this specific patient population.
What this means
The publication of the REDEFINE 2 study in the New England Journal of Medicine highlights the potential of cagrilintide-semaglutide as a therapeutic option for adults with Type 2 Diabetes and excess body weight. While specific quantitative results are not detailed in this summary, the study's focus on evaluating weight loss efficacy suggests a significant step forward in managing these co-occurring conditions. Clinicians and researchers will review the full publication for detailed efficacy and safety data to understand the complete clinical implications of this combination therapy.
Source
Information regarding this pivotal publication was obtained from PubMed, a database of biomedical literature. The article, titled "Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes," was published on 2025-01-01 in the New England Journal of Medicine, accessible via pubmed.ncbi.nlm.nih.gov.